CLOVIS EDUARDO SANTOS GALVAO
Projetos de Pesquisa
Unidades Organizacionais
Instituto Central, Hospital das Clínicas, Faculdade de Medicina - Médico
LIM/60 - Laboratório de Imunologia Clínica e Alergia, Hospital das Clínicas, Faculdade de Medicina
LIM/60 - Laboratório de Imunologia Clínica e Alergia, Hospital das Clínicas, Faculdade de Medicina
37 resultados
Resultados de Busca
Agora exibindo 1 - 10 de 37
bookPart Controle de exposição ambiental(2021) SOUZA, Bárbara de; GALVãO, Clóvis Eduardo Santos; AGONDI, Rosana CâmarabookPart Rinossinusite(2015) GALVãO, Clóvis Eduardo Santos- Efficacy of House Dust Mite Sublingual Immunotherapy in Patients with Atopic Dermatitis: A Randomized, Double-Blind, Placebo-Controlled Trial(2022) LANGER, Sarah Sella; CARDILI, Renata Nahas; MELO, Janaina Michelle Lima; FERRIANI, Mariana Paes Leme; MORENO, Adriana Santos; DIAS, Marina Mendonca; BUENO-FILHO, Roberto; POCENTE, Renata Helena Candido; ROXO-JUNIOR, Persio; SILVA, Jorgete; VALERA, Fabiana Cardoso Pereira; COELHO, Eduardo Barbosa; GALVAO, Clovis Eduardo Santos; CARMONA, Fabio; ARAGON, Davi Casale; ARRUDA, Luisa KarlaBACKGROUND: Sensitization to house dust mites (HDMs) is frequent in patients with atopic dermatitis. OBJECTIVE: To investigate the efficacy of sublingual immunotherapy (SLIT) with Dermatophagoides pteronyssinus extract in patients with atopic dermatitis sensitized to HDM. METHODS: In this randomized, double-blind, placebo-controlled trial, we enrolled 91 patients 3 years or older, with SCORing Atopic Dermatitis (SCORAD) score greater than or equal to 15 and positive skin test result and/or IgE to D pter-onyssinus. Patients were stratified according to age (<12 and >= 12 years) to receive HDM SLIT or placebo for 18 months. Primary outcome was a greater than or equal to 15-point decrease in SCORAD score. Secondary outcomes were decreases in SCORAD and objective SCORAD, Eczema Area and Severity Index, visual analog scale for symptoms, and pruritus scale scores; Investigator's Global Assessment 0/1; and decrease greater than or equal to 4 points in Dermatology Life Quality Index. Background therapy was maintained. RESULTS: A total of 66 patients completed the study (35 HDM SLIT, 31 placebo). After 18 months, 74.2% and 58% of patients in the HDM SLIT group and the placebo group, respectively, showed greater than or equal to 15-point decrease in SCORAD score (relative risk, 1.28; 95% CI, 0.89-1.83). Significant SCORAD score decreases from baseline of 55.6% and 34.5% in HDM SLIT and placebo groups (mean difference, 20.4; 95% CI, 3.89-37.3), significant objective SCORAD score decreases of 56.8% and 34.9% in HDM SLIT and placebo groups (mean difference, 21.3; 95% CI, 0.66-41.81), and more patients with Investigator's Global Assessment 0/1 in the HDM SLIT group as compared with the placebo group (14 of 35 vs 5 of 31; relative risk, 2.63; 95% CI, 1.09-6.39) were observed at 18 months. CONCLUSIONS: Our results suggest that HDM SLIT may be effective in HDM-sensitized patients as an add-on treatment for atopic dermatitis. (C) 2021 The Authors.
bookPart Abordagem clínica do paciente com doenças imunoalérgicas(2022) GALVãO, Clóvis Eduardo Santos; CASTRO, Fábio Fernandes MoratobookPart Anafilaxia(2016) LIMA, Cynthia Mafra Fonseca de; YANG, Ariana Campos; GALVãO, Clóvis Eduardo Santos; CASTRO, Fábio Fernandes MoratobookPart Imunoterapia alérgeno-específica(2021) WATANABE, Alexandra Sayuri; GALVãO, Clóvis Eduardo Santos- Work-related asthma (WRA) has worst socioeconomic status, quality of life and asthma control: a brazilian study(2019) ROIO, Lavinia Clara Del; TERRA-FILHO, Mario; ALGRANTI, Eduardo; GALVAO, Clovis Eduardo Santos; FREITAS, Jefferson Benedito Pires De; SANTOS, Ubiratan Paula
- Airway inflammatory profile among cleaning workers from different workplaces(2016) FELIX, Soraia Nogueira; AVONA, Monise Dematte; SANTOS, Bruna Gabryela Busoletto dos; PAZ, Edineia Rosa da; ALMEIDA, Francine Maria de; GENARO, Isabella Santos de; LIMA, Cynthia Mafra Fonseca de; GALVAO, Clovis Eduardo Santos; GARCIA, Maria Lucia Bueno; MARTINS, Milton de Arruda; ROMANHOLO, Beatriz Mangueira Saraiva
bookPart Diagnóstico das alergias no idoso(2015) GALVãO, Clóvis Eduardo Santos- Novel allergens from ancient foods: Man e 5 from manioc (Manihot esculenta Crantz) cross reacts with Hev b 5 from latex(2013) SANTOS, Keity Souza; GADERMAIER, Gabriele; VEJVAR, Eva; ARCURI, Helen Andrade; GALVAO, Clovis Eduardo; YANG, Ariana Campos; RESENDE, Virginia Maria Ferreira; MARTINS, Carlo de Oliveira; HIMLY, Martin; MARI, Adriano; LISO, Marina; POMPONI, Debora; BREITENEDER, Heimo; WAGNER, Stefan; KALIL, Jorge; FERREIRA, Fatima; CASTRO, Fabio Fernandes MoratoScope Manioc (Manihot esculenta) is a tuber mainly consumed in the Southern Hemisphere and used worldwide by food and chemistry industry. We aimed to recombinantly produce and characterize the first manioc allergen and evaluate its IgE reactivity in sera of Brazilian and Italian patients. Methods and results The molecule, termed Man e5, was expressed in E. coli, characterized by amino acid analysis, mass spectrometry, circular dichroism, HPLC, and dynamic light scattering. A tertiary structural model of the protein was produced using bioinformatics and susceptibility to pepsin digestion was analyzed in vitro. Based on its high content of charged residues, heat stability, flexibility and lack of secondary structure elements, the allergen was determined a member of the intrinsically disordered protein family. Brazilian patients were selected based on manioc allergy and Italians based on latex allergy and sensitization to Hev b 5.71% of Brazilians and 40% of Italians were in vitro IgE positive to Man e5. Cross-inhibition assays suggest a possible involvement of this allergen in the latex-fruit syndrome. Conclusion Man e5, the first purified allergen from manioc demonstrates IgE cross-reactivity with Hev b 5. Data suggest Hev b 5 might act as primary sensitizer and could therefore lead to allergic manifestations upon manioc consumption without prior exposition.